drugset
drugset / Trial / NCT02772718

An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery

NCT02772718 ↗

Phase 2 Completed 20 enrolled XOMA (US) LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and clinical pharmacology of XOMA 358 in patients with hypoglycemia after gastric bypass surgery.

Timeline

Start
2016-04
Primary completion
2021-05
Completion
2021-05

Outcome

Met primary endpoint

release “The study objective was met, with a clinically significant improvement in hypoglycemia by more than 50%” rezolutebio.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Ersodetug Monoclonal antibody — Intravenous

Indications

hypoglycemia